CN103232464B - 类紫杉醇化合物及其制备和在抗癌药物中的应用 - Google Patents
类紫杉醇化合物及其制备和在抗癌药物中的应用 Download PDFInfo
- Publication number
- CN103232464B CN103232464B CN201310118861.5A CN201310118861A CN103232464B CN 103232464 B CN103232464 B CN 103232464B CN 201310118861 A CN201310118861 A CN 201310118861A CN 103232464 B CN103232464 B CN 103232464B
- Authority
- CN
- China
- Prior art keywords
- compound
- taxoid
- dissolved
- mol ratio
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 title description 5
- 239000003814 drug Substances 0.000 title description 5
- 238000011275 oncology therapy Methods 0.000 title description 4
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 25
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 11
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 229940126214 compound 3 Drugs 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 229940125782 compound 2 Drugs 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000007821 HATU Substances 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical group O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000012044 organic layer Substances 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 claims description 2
- 238000002525 ultrasonication Methods 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 238000003786 synthesis reaction Methods 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 239000004593 Epoxy Substances 0.000 abstract description 6
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 abstract description 4
- 244000162450 Taxus cuspidata Species 0.000 abstract description 4
- 235000009065 Taxus cuspidata Nutrition 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000036457 multidrug resistance Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- -1 Methyl benzenesulfonyl Chemical group 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241001116500 Taxus Species 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical class CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310118861.5A CN103232464B (zh) | 2013-03-29 | 2013-03-29 | 类紫杉醇化合物及其制备和在抗癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310118861.5A CN103232464B (zh) | 2013-03-29 | 2013-03-29 | 类紫杉醇化合物及其制备和在抗癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103232464A CN103232464A (zh) | 2013-08-07 |
CN103232464B true CN103232464B (zh) | 2015-08-19 |
Family
ID=48880544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310118861.5A Expired - Fee Related CN103232464B (zh) | 2013-03-29 | 2013-03-29 | 类紫杉醇化合物及其制备和在抗癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103232464B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115181023B (zh) * | 2022-05-17 | 2023-07-28 | 东华理工大学 | 螺环活性增塑剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998008849A1 (de) * | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
CN100339373C (zh) * | 1995-12-13 | 2007-09-26 | 塞克化学有限公司 | 紫杉醇类似物的制备和作为抗肿瘤剂的应用 |
-
2013
- 2013-03-29 CN CN201310118861.5A patent/CN103232464B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100339373C (zh) * | 1995-12-13 | 2007-09-26 | 塞克化学有限公司 | 紫杉醇类似物的制备和作为抗肿瘤剂的应用 |
WO1998008849A1 (de) * | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
Non-Patent Citations (3)
Title |
---|
New and unusual scaffolds in medicinal chemistry;Charles M. Marson;《Chem. Soc. Rev.》;20111231;第40卷;第5514–5533页 * |
Synthesis of Azaspirocycles and their Evaluation in Drug Discovery;Jonannes A.Burkhard 等;《Angew. Chem. Int. Ed.》;20100401;第49卷;第3524-3527页 * |
Synthesis of extremely simplified compounds possessing the key pharmacophore units of taxol, phenylisoserine and oxetane moieties;Kaoru Fuji等;《Chem.Pharm.Bull》;19991231;第47卷(第9期);第1334-1337页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103232464A (zh) | 2013-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6, 7-seco-oridonin derivatives as novel potential anticancer agents | |
CN112079684A (zh) | 具有聚集诱导发光效应的柱芳烃及类柱芳烃化合物及其制备方法与应用 | |
CN101402655B (zh) | 一种米铂的制备方法 | |
CN103232464B (zh) | 类紫杉醇化合物及其制备和在抗癌药物中的应用 | |
CN111647040A (zh) | 一种天然活性多肽Tubulysin U的制备方法 | |
Eçik et al. | Synthesis and fluorescence properties of cyclophosphazenes containing thiazole or thiadiazole rings | |
CN110128482B (zh) | 一种具有肿瘤靶向的新型Pt(IV)配合物的制备方法及其应用 | |
CN110642740B (zh) | 异斯特维醇酰胺衍生物及其制备方法 | |
CN102060757B (zh) | 酰腙类Schiff碱化合物及其制备方法与应用 | |
CN111471080A (zh) | ocotillol型人参皂苷元A环并氨基噻唑环衍生物及制备方法 | |
CN113336798B (zh) | 一种基于三均嗪的三核铂配合物及其制备方法和应用 | |
Takjoo et al. | Effect of solvents in mixed-ligand supramolecular self-assembly architectures | |
CN106588826B (zh) | 阿司匹林紫杉醇抗癌药物偶联物、合成方法及其应用 | |
CN106632374B (zh) | 异甘露糖醇—双苯并咪唑盐类化合物及其制备方法 | |
CN102391351B (zh) | 一种具有抗肿瘤活性的积雪草酸修饰物及其制备方法 | |
CN104693156A (zh) | 9,10-二羟基-1-去氧紫杉醇类似物及其制备方法 | |
CN108530515A (zh) | 天然产物be-43547环状母核的制备方法 | |
CN110272337B (zh) | 6-姜酚衍生物及其制备和应用 | |
Chen et al. | Synthesis and spectroscopic characterization of some new piperazine phosphoramide derivatives of 4-hydroxycoumarin | |
Liu et al. | Synthesis and cancer cell cytotoxicity of gold (III) tetraarylporphyrins with a C5-carboxylate substituent | |
CN104892372B (zh) | 一种小分子聚乙二醇的合成方法 | |
CN103145676B (zh) | 7,4’–二取代异黄酮衍生物及其制备方法与应用 | |
CN106243104B (zh) | 一种对萘醌与嘧啶杂合体及其合成方法 | |
CN113666903B (zh) | 一种芝麻酚的制备方法 | |
CN103333131B (zh) | 一种2-胺基苯并恶唑类化合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SICHUAN AGRICULTURAL UNIVERSITY Free format text: FORMER OWNER: CHEN XINGXIU Effective date: 20150715 Free format text: FORMER OWNER: WANG DAN GAO FENG Effective date: 20150715 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150715 Address after: Ya'an City, Sichuan Province, 625014 new Yucheng Kang Road No. 46 Applicant after: Sichuan Agricultural University Address before: 611130 Huimin Road, Wenjiang District, Sichuan 211, Chengdu campus, Sichuan Agricultural Uniersity, Chengdu Applicant before: Chen Xingxiu Applicant before: Wang Dan Applicant before: Gao Feng |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Gao Feng Inventor after: Chen Xingxiu Inventor after: Wang Dan Inventor before: Chen Xingxiu |
|
COR | Change of bibliographic data | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 Termination date: 20170329 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Gao Feng Document name: Notification of Termination of Patent Right |